Geron (NASDAQ:GERN) Trading Down 3% – Time to Sell?

Geron Co. (NASDAQ:GERN)’s stock price traded down 3% during mid-day trading on Monday . The stock traded as low as $1.77 and last traded at $1.77. 1,451,958 shares traded hands during trading, a decline of 90% from the average session volume of 14,617,280 shares. The stock had previously closed at $1.82.

Wall Street Analyst Weigh In

A number of research analysts recently commented on GERN shares. B. Riley cut Geron from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $3.50 to $2.00 in a report on Thursday, February 27th. Stifel Nicolaus reduced their price objective on shares of Geron from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. Needham & Company LLC restated a “buy” rating and set a $5.00 target price on shares of Geron in a research report on Wednesday, March 12th. HC Wainwright reaffirmed a “neutral” rating on shares of Geron in a research note on Wednesday, March 12th. Finally, Barclays reiterated an “overweight” rating and issued a $4.00 price target (down previously from $9.00) on shares of Geron in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Geron has a consensus rating of “Moderate Buy” and an average price target of $5.75.

Geron Trading Down 2.9 %

The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. The company’s 50 day moving average price is $2.37 and its two-hundred day moving average price is $3.43. The firm has a market cap of $1.08 billion, a PE ratio of -5.31 and a beta of 0.53.

Geron (NASDAQ:GERN) last announced its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The business had revenue of $47.54 million during the quarter, compared to the consensus estimate of $45.29 million. As a group, sell-side analysts forecast that Geron Co. will post -0.25 EPS for the current year.

Institutional Trading of Geron

Hedge funds and other institutional investors have recently bought and sold shares of the business. SBI Securities Co. Ltd. purchased a new stake in shares of Geron during the fourth quarter valued at $28,000. Integrated Wealth Concepts LLC bought a new stake in Geron during the 4th quarter valued at about $36,000. GF Fund Management CO. LTD. purchased a new stake in Geron in the 4th quarter valued at about $45,000. 111 Capital bought a new position in Geron in the 4th quarter worth about $52,000. Finally, Fifth Lane Capital LP purchased a new position in shares of Geron during the fourth quarter worth approximately $53,000. Hedge funds and other institutional investors own 73.71% of the company’s stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.